Problems of leprosy relapse in China.
The proportion of relapses among all patients detected each year increased steadily since the initiation of the national leprosy control program in China with dapsone monotherapy in 1955, reaching 18%-24% in the more leprosy-endemic provinces along the coast. Relapses were also reported in the formerly rifampin-plus-dapsone-treated patients. So far, only three paucibacillary relapses after 6 months of multidrug therapy (MDT) have been reported, and these were due to misclassification at the time of diagnosis. A short course of MDT should be given to all formerly dapsone- and/or rifampin-plus-dapsone-cured patients for the prevention of relapse. If not, they should be screened every 1 to 2 years for any possible signs of relapse, and MDT given when needed.
Li
H Y
HY
Leprosy Unit, Beijing Tropical Medicine Research Institute, China.
D002681:China; D002991:Clofazimine / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007918:Leprosy / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D012008:Recurrence; D012189:Retrospective Studies; D012293:Rifampin / Q000627:therapeutic use*; D012307:Risk Factors
D003622:Dapsone; D002991:Clofazimine; D012293:Rifampin